





FIGURE 1

B



C




FIGURE 1 (CONTINUED)




FIGURE 2






FIGURE 3


A



B



C



D






FIGURE 4

6/21


E



F



G



H





FIGURE 4 (CONTINUED)

7/21

I



J




FIGURE 4 (CONTINUED)




FIGURE 5

9/21





FIGURE 5 (CONTINUED)

10/21

G

Hb



H

I





FIGURE 5 (CONTINUED)

11/21

J

K



L

M




FIGURE 5 (CONTINUED)




FIGURE 6

A




FIGURE 7

B




FIGURE 7 (CONTINUED)

15/21




FIGURE 8

Acute treatment
after Hb injection




FIGURE 9

17/21






FIGURE 10

A



B



Vehicle, VR81 or IgG control was administered 40 minutes after mG-CSF

FIGURE 11

19/21






FIGURE 12


E



F



G



H




FIGURE 12 CONTINUED

I




FIGURE 12 CONTINUED